J. Edwards
Keine laufenden Positionen mehr
Vermögen: 68 149 $ am 31.03.2024
Profil
J.
Michael Edwards worked as an Auditor at PricewaterhouseCoopers LLP from 1992 to 1995.
He then worked as a Chief Accounting Officer at U.S.
Global Investors, Inc. from 1997 to 1999.
From 2000 to 2001, he worked as an Assistant Controller at ILEX Oncology, Inc. He then worked as a Controller at BioNumerik Pharmaceuticals, Inc. from 2001 to 2006.
From 2006 to 2007, he worked as a Regional Director-Finance & Accounting at Fieldstone Utah Investors LLC.
He also worked as an Executive Vice President at TurboGenix, Inc. and as a Principal at Progress Energy, Inc., Planergy, Inc., and bioAffinity Technologies, Inc. In 2008, he worked as a Chief Financial Officer at Aviation Upgrade Technologies, Inc. and OncoVista, Inc. He then worked as a Chief Financial Officer at OncoVista Innovative Therapies, Inc. from 2008 to 2011 and at CytoBioscience, Inc. He received his undergraduate degree from the University of Texas at San Antonio and his MBA from the McCombs School of Business at the University of Texas at Austin.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 14.04.2023 | 33 737 ( 0,29% ) | 68 149 $ | 31.03.2024 |
Ehemalige bekannte Positionen von J. Edwards
| Unternehmen | Position | Ende |
|---|---|---|
| BIOAFFINITY TECHNOLOGIES, INC. | Director of Finance/CFO | 01.05.2023 |
| Aviation Upgrade Technologies, Inc. | Director of Finance/CFO | 14.01.2008 |
BioNumerik Pharmaceuticals, Inc.
 BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Comptroller/Controller/Auditor | 01.09.2006 |
Ausbildung von J. Edwards
| The University of Texas at Austin | Graduate Degree |
| McCombs School of Business | Masters Business Admin |
| University of Texas at San Antonio | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ONCOVISTA INNOVATIVE THERAPIES, INC. | Health Technology |
| U.S. GLOBAL INVESTORS, INC. | Miscellaneous |
| BIOAFFINITY TECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
ILEX Oncology, Inc.
 ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Health Technology |
Progress Energy, Inc.
 Progress Energy, Inc. Electric UtilitiesUtilities Progress Energy, Inc. is a public utility holding company. It engages in electric utilities and infrastructure activities. The company was founded on August 19, 1999 and is headquartered in Raleigh, NC. | Utilities |
| Aviation Upgrade Technologies, Inc. | Producer Manufacturing |
BioNumerik Pharmaceuticals, Inc.
BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Health Technology |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
